What is Semaglutide?
Semaglutide is an incretin medicine with product-specific uses in diabetes, weight management, and other defined conditions. Brand and formulation matter.
Video overview · 3:02
Semaglutide: What the Trials Actually Show (Ozempic, Wegovy and Rybelsus Explained)
How it copies the gut hormone GLP-1, what the STEP, SELECT and FLOW trials found for weight, heart and kidney outcomes, the side effects and label warnings, the trials still under way, and its FDA approvals.
Narrated with an AI voice from this profile's sources; education only, no dosing.
Read the transcript
Semaglutide is the medicine in Ozempic, Wegovy and Rybelsus, approved for type 2 diabetes, weight management, heart and kidney risk in certain people, and a form of fatty liver disease. It has been tested in trials with thousands of people. Here is what they actually show.
Semaglutide is a lab-made version of GLP-1, a gut hormone involved in appetite and blood sugar, built to last much longer in the body than the natural hormone. It boosts insulin when blood sugar is high, slows stomach emptying, and reduces appetite. How it protects the kidneys has not been worked out.
In STEP 1, nearly two thousand adults with obesity but no diabetes lost about fifteen percent of their weight on average over sixty-eight weeks, versus about two percent on placebo. In SELECT, over seventeen thousand people with heart disease and excess weight had a twenty percent lower risk of heart attack, stroke or heart-related death. In FLOW, people with diabetes and kidney disease had a twenty-four percent lower risk of serious kidney outcomes or heart or kidney death.
The most common side effects are digestive, like nausea, vomiting, diarrhea and constipation. The labels warn about pancreatitis and gallbladder disease, and in the SUSTAIN-6 diabetes trial, eye complications were more common than on placebo. There is also a boxed warning: semaglutide caused thyroid tumors in rodents, and whether it does in humans is unknown.
More answers are coming. The liver trial behind Wegovy's fatty liver approval is continuing for about four and a half years, to see whether semaglutide keeps people free of cirrhosis. Another trial is tracking diabetic eye disease over five years, with results expected in 2027.
Semaglutide is FDA approved. Ozempic was approved in 2017 for type 2 diabetes, and later to lower heart and kidney risks in some people with diabetes. Rybelsus is a tablet for diabetes. Wegovy is approved for weight management, heart-risk reduction and a form of fatty liver disease. Compounded copies are not FDA approved, and the FDA has warned sellers of so-called research versions.
Do Ozempic and Wegovy contain the same drug? Yes, both are semaglutide, approved for different uses. Does the weight stay off after stopping? In STEP 4, people switched to placebo regained much of what they had lost. And is research-labeled semaglutide the real drug? PepsRadar's claim check says that is not supported. Tested online products have shown low purity, and the FDA warns that counterfeit Ozempic has been found in the US.
The bottom line: semaglutide is an approved medicine with strong evidence for weight loss, and for heart and kidney benefits in specific groups, plus common digestive side effects. For every study and source, see the semaglutide profile on PepsRadar dot com.
Biological role or research focus
Incretin signaling and appetite regulation.
Brand, formulation, and indication matter. An approved product does not validate a research-use-only version.
Role reference: MedlinePlus: Semaglutide injection ↗
Names you may encounter
Ozempic · Wegovy · Rybelsus
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- GLP-1 receptor agonist
- Main research area
- Metabolic and indication-specific outcomes
- Evidence featured
- Human randomized trial
- Source check
- October 4, 2026
Quick answers
- Is Semaglutide FDA approved?
- Yes. Ozempic (NDA 209637, 2017) for type 2 diabetes, with later approvals to lower heart risk (2020) and kidney-disease worsening and heart-related death (January 2025) in adults with type 2 diabetes. Source ↗
- Is Semaglutide safe?
- Semaglutide is a widely used GLP-1 drug; stomach side effects are common, and the label warns of thyroid C-cell tumors in rodents, pancreatitis, gallbladder disease and diabetic eye complications. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Semaglutide banned in sport?
- It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗
- Has the FDA taken action over Semaglutide?
- Yes. Our records list 4 FDA actions naming it, most recently on November 9, 2026: FDA Drug Safety Communication requiring all GLP-1 receptor agonist labels to add a warning about a potential increased risk of NAION (non-arteritic anterior ischemic optic neuropathy), a rare optic nerve condition that can cause sudden, painless vision loss in one eye, including permanent loss. Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| STEP 1 (2021) | Human randomized trial | 1,961 adults with obesity, or overweight with a weight-related condition, without diabetes. |
| FLOW kidney outcomes (2024) | Human randomized trial | 3,533 adults with type 2 diabetes and chronic kidney disease. |
| SELECT cardiovascular outcomes (2023) | Human randomized trial | 17,604 adults aged 45 or older with established cardiovascular disease, BMI at least 27, and no history of diabetes. |
| STEP 4 · continuation versus withdrawal (2021) | Human randomized withdrawal trial | 803 adults without diabetes who completed a 20-week semaglutide run-in and reached the studied maintenance regimen; 902 initially entered run-in. |
Claim check
False Is 'research' retatrutide or semaglutide the same as the real drug?
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 2021
STEP 1
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Population / model
- 1,961 adults with obesity, or overweight with a weight-related condition, without diabetes.
- Study design
- Semaglutide versus placebo for 68 weeks, alongside lifestyle intervention.
- Main finding
- Mean weight change was −14.9% versus −2.4%, a 12.4-percentage-point estimated difference. Gastrointestinal effects were common.
- Limits & context
- These are average results for a specific injectable regimen and trial population. The study is not a comparison with tirzepatide and cannot validate compounded or research-use products.
Source: Once-Weekly Semaglutide in Adults with Overweight or Obesity. ↗
Human randomized trial · 2024
FLOW kidney outcomes
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
- Population / model
- 3,533 adults with type 2 diabetes and chronic kidney disease.
- Study design
- Randomized placebo-controlled trial of once-weekly injected semaglutide; stopped early at a prespecified interim analysis because of benefit, after a median 3.4 years.
- Main finding
- Major kidney disease events (kidney failure, a fall in kidney function of at least half, or death from kidney or cardiovascular causes) were 24% lower with semaglutide (hazard ratio 0.76). Death from cardiovascular causes and from any cause were also lower, and serious adverse events were slightly less common (49.6% vs 53.8%).
- Limits & context
- Applies to people with type 2 diabetes and established kidney disease. Trials stopped early for benefit can overstate the effect, and the trial says nothing about people without diabetes or about research-use products.
Source: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes ↗
Human randomized trial · 2023
SELECT cardiovascular outcomes
Did treatment affect cardiovascular events in people without diabetes?
- Population / model
- 17,604 adults aged 45 or older with established cardiovascular disease, BMI at least 27, and no history of diabetes.
- Study design
- Double-blind placebo-controlled trial of the studied semaglutide formulation; mean follow-up 39.8 months.
- Main finding
- Cardiovascular death, nonfatal heart attack, or nonfatal stroke occurred in 6.5% of the semaglutide group and 8.0% of the placebo group. Hazard ratio 0.80 (95% CI 0.72–0.90). Adverse events led to permanent treatment discontinuation in 16.6% versus 8.2%.
- How to read it
- The observed event proportions differ by 1.5 percentage points. The hazard ratio describes relative event rates over follow-up; it is not a 20-percentage-point absolute reduction.
- Limits & context
- This population already had cardiovascular disease. The result does not establish the same benefit in every person seeking weight loss or validate unregulated preparations. Funded by Novo Nordisk.
Human randomized withdrawal trial · 2021
STEP 4 · continuation versus withdrawal
What happened after continuing treatment or switching to placebo?
- Population / model
- 803 adults without diabetes who completed a 20-week semaglutide run-in and reached the studied maintenance regimen; 902 initially entered run-in.
- Study design
- Double-blind randomized withdrawal comparison over a further 48 weeks, with lifestyle intervention in both groups.
- Main finding
- From randomization at week 20 to week 68, weight changed by −7.9% with continued semaglutide versus +6.9% after switching to placebo. Gastrointestinal events occurred in 49.1% versus 26.1%.
- How to read it
- These changes start at randomization, after the initial run-in loss. They are not percentages measured from the original baseline.
- Limits & context
- People unable to reach the regimen during run-in were not randomized. This selected population limits generalization to everyone starting treatment. It is not a trial of tapering or an individualized stopping strategy.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
80 registered studies name Semaglutide as an intervention among the 100 most recently updated of 811 search results; 44 are recruiting or under way, 18 have not started recruiting yet and 18 completed. Checked November 16, 2026 on ClinicalTrials.gov.
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 80 listed studies.
Search additional PubMed records ↗Risks & interactions
Semaglutide is a widely used GLP-1 drug; stomach side effects are common, and the label warns of thyroid C-cell tumors in rodents, pancreatitis, gallbladder disease and diabetic eye complications.
Caused thyroid C-cell tumors in rodents; it is unknown whether it does in humans. Do not use with a personal or family history of medullary thyroid carcinoma or with MEN 2.
Safety is established by FDA labeling and large trials. This entry summarizes the Ozempic label; other semaglutide products have their own labels. Whether the rodent thyroid tumors matter for humans is unknown, and pregnancy data are limited.
Take extra care with: Diabetes or blood-sugar medicinesCancer, now or in the pastPregnancy or breastfeedingKidney problems
From the FDA label lists below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.
Who should not use it
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Serious allergy to semaglutide or any ingredient
- Severe gastroparesis (very slow stomach emptying): not recommended
- Pregnancy, when used for weight loss (Wegovy): no benefit and possible fetal harm, and the label says to stop when pregnancy is recognized
Interactions
- Insulin or sulfonylureas: higher risk of low blood sugar, including severe episodes
- Oral medicines: slowed stomach emptying may change how they are absorbed
Serious risks
- Acute pancreatitis
- Worsening diabetic eye disease (retinopathy)
- Kidney injury from dehydration
- Severe stomach and bowel side effects
- Gallbladder disease
- Serious allergic reactions, and inhaling stomach contents during anesthesia or deep sedation
Common side effects
- nausea
- vomiting
- diarrhea
- abdominal pain
- constipation
Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: DailyMed: Ozempic (semaglutide) prescribing information ↗ · Wegovy prescribing information (DailyMed) ↗
Side effects by the numbers: how common are they?
In STEP 1 (1,961 adults without diabetes, 68 weeks), stomach and gut side effects were reported by 74.2% of people on semaglutide versus 47.9% on placebo. On semaglutide, 44.2% reported nausea, 31.5% diarrhea, 24.8% vomiting and 23.4% constipation. Most were mild to moderate and eased over time, but 4.5% stopped treatment because of them, versus 0.8% on placebo. Gallbladder problems, mostly gallstones, affected 2.6% versus 1.2%.
Source: Wilding et al. · NEJM · STEP 1 · 2021 ↗
The 2026 vision warning (NAION)
In November 2026 the FDA required all GLP-1 medicines, semaglutide included, to warn about NAION, a rare optic-nerve condition that causes sudden, painless vision loss in one eye. Across 126 trials it occurred 6.4 times per 100,000 person-years on GLP-1 medicines versus 3.8 on comparators, based on 15 cases in all. Sudden vision loss, blind spots or blurring in one eye need a same-day call to a health care professional. The NAION article under Research guides below has the full numbers.
Source: FDA Drug Safety Communication: GLP-1 receptor agonists and NAION (November 2026) ↗
Key precautions
Gastrointestinal effects, dehydration, gallbladder and pancreatic problems, retinopathy considerations, and thyroid-tumor warnings require review. Other glucose-lowering medicines can alter hypoglycemia risk.
Source: MedlinePlus: Semaglutide injection ↗
Regulatory status
- U.S. FDA approval
- Approved
Ozempic (NDA 209637, 2017) for type 2 diabetes, with later approvals to lower heart risk (2020) and kidney-disease worsening and heart-related death (January 2025) in adults with type 2 diabetes; Rybelsus tablets (NDA 213182, 2019) for type 2 diabetes; Wegovy injection (NDA 215256, 2021) for weight management, cardiovascular risk reduction and MASH; Wegovy tablets (NDA 218316) approved December 22, 2025. source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source - World Anti-Doping Agency (2026)
- Not on the WADA Prohibited List
Not prohibited. Semaglutide markers are on WADA's 2026 Monitoring Program (tracked for misuse patterns, not banned). source
FDA actions
- FDA proposed excluding semaglutide (with tirzepatide and liraglutide) from the 503B bulks list, finding no clinical need for outsourcing facilities to compound it from bulk. (2026-04-30) source
- FDA statement announcing intent to restrict GLP-1 APIs used in mass-marketed non-approved compounded drugs and to act on misleading marketing. (2026-02-06) source
- FDA page on risks of unapproved and compounded GLP-1 drugs, including dosing errors, fraudulent products and "research use only" sellers (updated October 1, 2026). (2026-10-01) source
- FDA Drug Safety Communication requiring all GLP-1 receptor agonist labels to add a warning about a potential increased risk of NAION (non-arteritic anterior ischemic optic neuropathy), a rare optic nerve condition that can cause sudden, painless vision loss in one eye, including permanent loss. Across 126 randomized trials (134,253 patients), NAION occurred 6.4 times per 100,000 person-years on GLP-1 drugs versus 3.8 on placebo or other diabetes drugs. FDA advises patients to contact a health care professional right away if they notice sudden vision loss in one eye, blind spots, color distortion or blurry spots, and says anyone who has had NAION should talk with their health care professional about whether to continue the medicine. (2026-11-09) source
Other notes
- Semaglutide is one of the GLP-1 active ingredients covered by FDA Import Alert 66-80 (detention without physical examination of GLP-1 bulk drug substances from non-green-listed makers; revised September 2026). source
- WADA 2026 Monitoring Program includes markers of semaglutide (in and out of competition). source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Clinical uses & product context
The current injection reference includes selected diabetes, weight-management, cardiovascular, kidney, and noncirrhotic MASH contexts. Eligibility and approval attach to the exact product and population; this is not a single unrestricted indication.
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
PepsRadar does not list, compare or link GLP-1-class products, even though some sellers we track elsewhere on the site also sell them. The approved medicine is available only with a prescription, through a pharmacy. The FDA warns that versions sold online as "research" products are unapproved and of unknown quality (FDA).
Mechanism & research rationale
It supports glucose-dependent insulin release, slows stomach emptying, and affects appetite. Separate trials are needed to establish weight, cardiovascular, kidney, or liver outcomes.
Molecular structure
Questions worth asking
- Which exact product is being discussed?
- Is a podcast describing a study, an approved indication, or a personal experience?
- Brand, formulation, and indication matter. An approved product does not validate a research-use-only version.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Video & podcast discussions: members library
Frequently asked questions
What are the dangers of semaglutide?
The common problems are stomach and gut side effects: in STEP 1, 74.2% on semaglutide reported them versus 47.9% on placebo, and 4.5% stopped treatment because of them. Less common risks on the label include gallbladder problems, pancreatitis and dehydration, and the FDA added a warning in 2026 about NAION, a rare cause of sudden vision loss in one eye. The label also carries a boxed warning about thyroid C-cell tumors seen in rodents, with human relevance unknown. These risks are weighed against proven benefits such as fewer heart attacks and strokes in SELECT.
Is STEP 1 evidence for every semaglutide formulation?
No. It studied a particular injectable regimen and population without diabetes.
Source: Once-Weekly Semaglutide in Adults with Overweight or Obesity. ↗
Can its percentage weight loss be ranked directly against another trial?
Different populations and study methods can distort such comparisons. A direct randomized comparison is more informative.
Source: Once-Weekly Semaglutide in Adults with Overweight or Obesity. ↗
What does the SELECT cardiovascular outcomes study show, and what does it not?
The observed event proportions differ by 1.5 percentage points. The hazard ratio describes relative event rates over follow-up; it is not a 20-percentage-point absolute reduction. This population already had cardiovascular disease. The result does not establish the same benefit in every person seeking weight loss or validate unregulated preparations. Funded by Novo Nordisk.
References & editorial record
- FDA · Unapproved GLP-1 products ↗
- MedlinePlus: Semaglutide injection ↗
- Once-Weekly Semaglutide in Adults with Overweight or Obesity. ↗
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes ↗
- Lincoff et al. · NEJM · SELECT · 2023 ↗
- Rubino et al. · JAMA · STEP 4 · 2021 ↗
- FDA Drug Safety Communication: GLP-1 receptor agonists and NAION (November 2026) ↗
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
PUT THE EVIDENCE IN CONTEXT
Research guides
RESEARCH FIELD GUIDE
From a promising mechanism to a useful finding
A practical way to read peptide research without turning an interesting experiment into a clinical promise.
Read the guide →RESEARCH FIELD GUIDE
Semaglutide, tirzepatide, retatrutide: why trial context changes the comparison
Understand direct comparisons, diabetes versus obesity populations, and the difference between glucose, weight, and cardiovascular outcomes.
Read the guide →RESEARCH FIELD GUIDE
Are peptides legal? FDA approval, research-use labels and steroids, explained
Some peptides are FDA-approved prescription drugs; most sold online are not. What the FDA has actually said, how pharmacy compounding fits in, and why peptides are not steroids.
Read the guide →RESEARCH FIELD GUIDE
Can peptides cause cancer? What drug labels, animal studies and case reports show
Some approved peptide drugs carry cancer warnings, some research peptides raise concerns from lab work, and a few case reports make headlines. What each kind of evidence can and can’t show.
Read the guide →RESEARCH FIELD GUIDE
Semaglutide not working? Why some people lose less, and what the trials show
Most people on semaglutide lose meaningful weight, but not everyone does. How many respond in the trials, why people with type 2 diabetes tend to lose less, what a new gene study found, and what the evidence says about switching or stopping.
Read the guide →RESEARCH FIELD GUIDE
Semaglutide and NAION: the FDA’s new vision warning, in numbers
On November 9, 2026 the FDA required every GLP-1 medicine, including semaglutide (Ozempic, Wegovy, Rybelsus), to carry a warning about NAION, a rare optic-nerve condition. How rare it is, where the concern came from, how strong the evidence is, and which symptoms need a same-day call.
Read the guide →RESEARCH FIELD GUIDE
What happens when you stop semaglutide? What the trials show
In the trials, most people who stopped semaglutide (Ozempic, Wegovy) regained much of the weight within a year, and gains in blood pressure and blood sugar faded too. The numbers from STEP 1, STEP 4 and tirzepatide’s SURMOUNT-4, and what the evidence says may help.
Read the guide →RESEARCH FIELD GUIDE
Semaglutide vs tirzepatide: what the head-to-head trials show
Only two randomized trials have compared semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) directly. Tirzepatide led to more weight loss in both. Here are the numbers, the side effects, the different heart-outcome evidence for each, and the caveats.
Read the guide →RESEARCH FIELD GUIDE
Orforglipron (Foundayo): the GLP-1 pill, explained
Orforglipron (Foundayo) is a once-daily GLP-1 pill the FDA approved for weight loss in April 2026. What it is, why it isn’t a peptide, what the ATTAIN and ACHIEVE trials found, how it compares with the injections, and its side effects and warnings.
Read the guide →RESEARCH FIELD GUIDE
When will retatrutide be approved? Where Lilly’s FDA application stands
Retatrutide is not approved anywhere yet. Eli Lilly says it plans to submit it to the FDA in the first quarter of 2027. How long FDA review usually takes, what the application will rest on, and why nothing sold as retatrutide today is the real thing.
Read the guide →RESEARCH FIELD GUIDE
The Wegovy pill vs Foundayo: the two GLP-1 weight-loss pills compared
The Wegovy pill (oral semaglutide) and Foundayo (orforglipron) are the two FDA-approved GLP-1 pills for weight loss. How they differ as drugs, how each is taken, what OASIS 4 and ATTAIN-1 found, side effects, and why there is no head-to-head answer yet.
Read the guide →RESEARCH FIELD GUIDE
GLP-1 side effects compared: semaglutide, tirzepatide, retatrutide and orforglipron
Stomach and gut problems topped the side-effect list in the main obesity trials of all four drugs. What STEP 1, SURMOUNT-1, TRIUMPH-1 and ATTAIN-1 reported, why the numbers don't line up neatly, and the warnings the class shares.
Read the guide →RESEARCH FIELD GUIDE
CagriSema: where Novo Nordisk's cagrilintide combination stands
CagriSema pairs cagrilintide, a long-acting amylin analogue, with semaglutide in one weekly shot. It cut weight about 20% in its main trial, trailed tirzepatide head to head, and is awaiting an FDA decision. It is not approved.
Read the guide →RESEARCH FIELD GUIDE
GLP-1s and muscle: how much lean mass do you lose, and does lifting help?
Body scans from semaglutide and tirzepatide trials show that part of the weight lost is lean mass. Here is how much, why lean mass is not the same as muscle, what a 2026 trial found when people lifted weights, and what is still unknown.
Read the guide →RESEARCH FIELD GUIDE
GLP-1s and keto: a real-food playbook for losing fat, not muscle
A GLP-1 medicine turns down your appetite. What you eat with that smaller appetite decides how much of the weight you lose is fat and how much is muscle. Lived experience and the published research on cutting carbs, ketones, electrolytes, kidney stones, muscle, fasting, real food and sleep, including where the evidence is thin.
Read the guide →














